For most of your life with heart failure, the answer has been a pill: a beta-blocker, an ACE inhibitor, a diuretic. But there is a point — usually when your ejection fraction sits at or below 35% despite months of optimal medication — where the question changes. It is no longer "which drug." It becomes "which device, or which surgery." This article walks through that decision the way a Chinese cardiac center actually makes it, so you can understand where you are on the path and what each next step costs.

Our dedicated advanced heart failure page collects the full pathway, hospitals and costs in one place; this post explains the logic behind it.

1. Who This Is For

You are on this path if two or more of the following sound familiar:

  • Your ejection fraction (EF) is 35% or lower
  • You still have symptoms after three or more months of optimal medication
  • You have been hospitalized more than once for heart failure
  • Your ECG shows left bundle branch block (LBBB) or a widened QRS
  • You have severe mitral regurgitation or aortic valve disease
  • Your doctor has said you may need a CRT, ICD, LVAD, or transplant

If that describes you, the useful frame is not "find a hospital" but "find out which stage you are at." That is what the rest of this covers.

2. The Decision Path, Step by Step

Chinese cardiac centers run advanced heart failure through a multidisciplinary team (MDT) that follows a roughly four-stage sequence. The order matters: each step is cheaper and less invasive than the one after it, so doctors confirm it will not work before moving on.

Step 1 — Find the cause. The team first classifies the failure: ischemic (blocked arteries), valvular (a faulty valve), electrical (dyssynchrony), congenital, or from cardiomyopathy. Every later decision depends on this answer, because a reversible cause is treated differently from a wiring or pump problem.

Step 2 — Protect against sudden death (ICD). If the EF is very low, the immediate risk is not just worsening symptoms but a fatal arrhythmia. An implantable cardioverter-defibrillator (ICD) — single-chamber, dual-chamber, or the newer subcutaneous EV-ICD — is placed to shock a dangerous rhythm back to normal. This is often the first device decision, independent of the other steps.

Step 3 — Fix the rhythm or the reversible cause. If the ECG shows LBBB or a widened QRS, the heart's two lower chambers are beating out of sync. Cardiac resynchronization therapy (CRT-P, or CRT-D when combined with a defibrillator) re-coordinates them. If there is no conduction problem, the team instead corrects what is reversible: coronary stenting or bypass (CABG), valve repair or replacement (TAVR/TEER), or a congenital defect repair.

Step 4 — Strengthen, then support. If the heart still fails after the above, cardiac contractility modulation (CCM) may strengthen its contraction. When the heart no longer responds to any of it, the options narrow to a left ventricular assist device (LVAD) or a heart transplant, coordinated at a transplant center.

The key insight for a patient: most people do not need to jump to Step 4. A large share of advanced heart failure is settled at Steps 2 and 3, with a device or a valve that fixes a specific problem rather than a full transplant.

What the numbers have to be

"Widened QRS" and "low EF" are not thresholds — they are shorthand. The actual cut-offs in China's 2024 heart failure guideline are specific, and knowing them tells you which conversation you are actually in:

DecisionWhat the team looks for
ICD (sudden-death protection)EF ≤35% with NYHA class II–III symptoms. After a heart attack, at least 40 days. For non-ischaemic causes, at least three months on optimised medication. Expected survival beyond a year. Not implanted in end-stage NYHA class IV.
CRT (resynchronisation)Sinus rhythm, EF ≤35%, still symptomatic, and a wide QRS. The strongest indication is LBBB with QRS ≥150 ms. LBBB with QRS 120–149 ms is a stronger indication in women than in men. Non-LBBB with QRS ≥150 ms is a weaker indication. A QRS below 130 ms is not an indication.
CCMA narrow QRS (under 130 ms) where CRT does not apply, EF 25–45%, still symptomatic on optimal medication.
TEER (mitral repair)Moderate-to-severe or worse mitral regurgitation, one to three months of optimised medication (or CRT) with persistent NYHA III–IV symptoms, EF 20–50%, left-ventricular end-systolic diameter ≤70 mm, and pulmonary artery systolic pressure ≤70 mmHg. Severe right-heart impairment or severe tricuspid regurgitation rules it out.
LVADEF below 25% with peak oxygen uptake under 12 ml/kg/min, or three or more unplanned heart-failure hospitalisations in twelve months, or dependence on intravenous inotropes, or progressive kidney/liver decline from poor perfusion. Severe right-heart failure and severe tricuspid regurgitation rule it out.

Read the left column as what the hospital team measures against, not as a self-assessment you can run at home. An EF of 34% does not entitle you to an ICD and an EF of 36% does not disqualify you — the team weighs the whole picture, including why the heart is failing and how long you have left to benefit.

3. What Each Stage Costs

Reference prices, converted at roughly 7.2 CNY per US dollar. These are estimates. The final quote comes from the hospital after it reviews your records.

TreatmentReference cost (China)Note
ICD — single chamber≈ $13,750sudden-death protection
ICD — dual chamber≈ $16,400sudden-death protection
CRT-D (resynchronization + defibrillator)≈ $20,600for LBBB / widened QRS
CCM (contractility modulation)≈ $27,500when devices and surgery fall short
Coronary bypass (CABG)$18,000–$45,000for ischemic heart failure
Valve repair / replacement (TAVR/TEER)$10,000–$15,000for valvular heart failure
LVAD≈ $123,600bridge to transplant or destination
Heart transplantcase-specificquoted after MDT review

Two numbers stand out. The device tier (ICD, CRT, CCM) sits in a narrow $13,000 to $28,000 band, which is the range where most advanced heart-failure care is decided. LVAD and transplant are a different order of magnitude, which is precisely why the decision path exhausts Steps 2 and 3 first.

4. Where Each Stage Is Best Handled

Different centers lead at different stages, and matching the stage to the hospital matters more than picking a single "best" name.

  • Foshan Fosun Chancheng Hospital (Foshan, near Guangzhou) — a Grade 3A hospital with a dedicated international medical center serving 124+ countries, multilingual staff, and halal-meal and prayer-room support. A strong entry point for Southeast Asian patients, including Malaysia, for assessment and device therapy. See Fosun Chancheng.
  • Fu Wai Hospital (Beijing) — China's national cardiovascular center, around 18,000+ cardiac surgeries a year across device, valve, and transplant work. See Fu Wai.
  • Anzhen Hospital (Beijing) — a high-volume cardiovascular center with a dedicated heart-failure and device program. See Anzhen.
  • Zhongshan Hospital (Shanghai) — strong in valve and structural heart intervention alongside heart failure. See Zhongshan.
  • Guangdong Provincial People's Hospital (Guangzhou) — the leading southern China center for heart failure and device therapy. See GDPH.
  • Xijing Hospital (Xi'an) — one of China's highest-volume heart transplant programs, for the end-stage cases. See Xijing.

The full selection logic, including why no single center tops every stage, is on our methodology page.

5. Conduction system pacing: a newer alternative to CRT

Standard CRT threads a third lead through a vein on the outside of the left ventricle. A newer approach wires the heart's own conduction system instead — either at the His bundle, or further down at the left bundle branch (left bundle branch pacing, LBBP).

The appeal is that the impulse then travels down the heart's native pathway rather than spreading across the muscle wall, so electrical activation can be restored close to normal. In a classic left bundle branch block, adjusting the atrioventricular delay can bring the paced QRS close to normal width.

The concept is old — functional longitudinal dissociation within the His bundle was described in 1919, and pacing the distal His to correct LBBB confirmed that a bundle-branch block can originate in the His itself. What changed is the hardware: dedicated leads and delivery sheaths have made left bundle branch pacing reproducible outside a handful of expert centres.

For a patient, the practical question is availability, not technique. Conduction system pacing is performed at China's larger device centres; whether it is offered where you are treated is the thing to ask. The two questions worth putting to the hospital are whether it performs conduction system pacing at all, and whether you are a candidate for it rather than for standard CRT.

6. Other devices and supportive options

Beyond CRT, ICD and LVAD, the pathway includes options that address one specific problem rather than the pump itself.

  • Ultrafiltration. For acute heart failure with a fluid load that no longer responds to diuretics, a machine removes excess fluid directly and in a controlled way. It is a rescue measure for congestion, not a treatment for the underlying failure.
  • CardioMEMS. A small wireless sensor implanted in the pulmonary artery measures pressure remotely, so doctors can read the trend between visits and adjust medication before symptoms return. Established abroad; being introduced in China.
  • CPAP for obstructive sleep apnoea. Sleep apnoea is common in heart failure and makes it worse, and continuous positive airway pressure treats the obstruction. This is supportive care alongside heart-failure treatment, not a substitute for it.
  • Servo-ventilation — the one negative. Servo-ventilation is not recommended for patients with reduced ejection fraction and central sleep apnoea, because it was associated with increased mortality. If you have central rather than obstructive apnoea, this distinction matters.

One honest note on CCM, because it is often presented as a fourth pillar alongside CRT and ICD. It is CE-marked, it is performed at a growing number of Chinese centres, and the FIX-HF-5C trial reported improvements in peak oxygen uptake, six-minute walk distance, quality of life and heart-failure hospitalisation. It has not entered China's 2024 guideline as a formal recommendation. Treat it as an emerging option rather than an established step, and ask the hospital how many it has performed.

7. What This Does Not Promise

Three honest limits, because end-stage heart failure invites overstatement:

  1. A device is not a cure. CRT, ICD and CCM manage symptoms and reduce risk; they do not reverse the underlying disease. An LVAD or transplant carries real surgical risk and a long recovery.
  2. The prices are estimates. Device cost can shift with the specific model, whether it is imported or domestic, and your clinical complexity. Get a written quote before committing.
  3. Eligibility is decided by an MDT, not by a website. Whether you qualify for CRT versus LVAD versus transplant depends on your records, which a multidisciplinary team must review. No intermediary can promise a specific treatment in advance.

The honest frame is: China's advantage is speed and volume — scheduling within two to four weeks at centers that perform thousands of these procedures a year — not a guarantee of a particular outcome.


8. Frequently Asked Questions

Am I a candidate for advanced heart failure treatment in China?

This pathway is for patients with an EF of 35% or lower who still have symptoms after three or more months of optimal medication, have had repeated heart-failure hospitalizations, or whose doctor has said they may need CRT, ICD, LVAD or transplant. A free case review with your records confirms eligibility.

What is the difference between CRT, ICD, CCM and LVAD?

An ICD protects against sudden cardiac death. CRT re-coordinates a poorly synchronized heartbeat and is often combined with an ICD (CRT-D). CCM strengthens the heart's contraction. An LVAD is an implanted pump that supports the heart when the others are no longer enough, usually as a bridge to transplant or as long-term destination therapy.

How much do these devices and procedures cost in China?

Reference prices: CRT-D about $20,600, single-chamber ICD about $13,750, dual-chamber ICD about $16,400, CCM about $27,500 and LVAD about $123,600. CABG runs $18,000–$45,000 and valve replacement $10,000–$15,000. Final quotes depend on the device and your clinical complexity.

Which hospital is best for advanced heart failure in China?

Foshan Fosun Chancheng is a Grade 3A hospital with a dedicated international medical center and multilingual, halal-friendly care, a strong choice for Southeast Asian patients. Fu Wai (Beijing) is China's number-one cardiology center, and Anzhen (Beijing), Zhongshan (Shanghai), Guangdong Provincial People's Hospital (Guangzhou) and Xijing (Xi'an) lead in device therapy and transplant.

Do you offer heart transplant for international patients?

Heart transplant and LVAD are available at China's top cardiac centers, coordinated case by case. Eligibility, timing and cost are confirmed after a multidisciplinary review of your records.


Get a Free Heart Failure Case Review

Tell us your diagnosis, ejection fraction and recent test results. We'll match you with two to three verified cardiac centers, clarify which device or surgical path may apply to your stage, and outline the next practical step. No obligation, 100% confidential, we reply within 24 hours.

  • 📧 Email: contact@chinahospitalsguide.com
  • 💬 WhatsApp: +86 157 6310 7083
  • 📨 Telegram: @chinahospitalguide
  • 💬 WeChat: chinahospitalguide
  • 🌐 Start Free Case Review

Medical Disclaimer This article is general educational content and does not constitute medical advice, a treatment recommendation, or an invitation to seek care. It cannot replace an in-person consultation with a licensed physician. Device and procedure prices are reference estimates converted at roughly 7.2 CNY per US dollar and are not guarantees; final quotes come from the hospital after review of your records. Whether a treatment is suitable must be assessed by a qualified multidisciplinary team.

Source disclosure The clinical pathway is based on Fosun Health's advanced heart failure decision tree. Hospital program details are drawn from the official profiles of Fu Wai, Anzhen, Zhongshan (Shanghai), Guangdong Provincial People's Hospital, and Xijing Hospital. China Hospitals Guide is an independent hospital-matching platform and does not accept commissions from hospitals.

Related Reading